# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate o...
HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...
Consistent safety and efficacy profiles across adult and pediatric populations – Majority of pediatric patients who achieved...
HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...
HC Wainwright & Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pri...
– PDUFA action date set for September 26, 2024 –– NDA being reviewed under FDA's RTOR program –
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target f...